In this article, we will take a look at the 5 top performing European stocks so far in 2023. To see more such companies, go directly to 15 Top Performing European Stocks So Far in 2023.
5. VIA optronics AG (NYSE:VIAO)
YTD Gains as of March 23: 68%
Germany-based VIA optronics AG (NYSE:VIAO) is a display solutions company. VIA optronics AG (NYSE:VIAO) has gained 68% year to date through March 23. In November, VIA optronics AG (NYSE:VIAO) posted its Q3 results. GAAP EPS in the quarter came in at €0.27. Revenue in the quarter increased by 27.3% on a YoY basis to a total of €62.9 million.
3 hedge funds tracked by Insider Monkey had stakes in VIA optronics AG (NYSE:VIAO). The biggest hedge fund stakeholder of VIA optronics AG (NYSE:VIAO) during this period was J. Carlo Cannell’s Cannell Capital, with a $2.7 million stake.
4. Celyad Oncology SA (NASDAQ:CYAD)
YTD Gains as of March 23: 77%
Belgium-based Celyad Oncology SA (NASDAQ:CYAD) uses chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Celyad Oncology SA (NASDAQ:CYAD) ranks 4th in our list of the top performing European stocks so far in 2023. Celyad Oncology SA (NASDAQ:CYAD) however fell a whopping 30% earlier this month after the company said it will recognize a non-cash impairment of its goodwill and intangible oncology assets. Celyad Oncology SA (NASDAQ:CYAD) also said its board plans to submit a vote for its business plan, including a proposal to continue the company’s activities at the shareholders’ meeting.
Michael Novogratz’s Fortress Investment Group owns a $3.2 million stake in Celyad Oncology SA (NASDAQ:CYAD) as of the end of the fourth quarter of 2022.
3. SOPHiA GENETICS SA (NASDAQ:SOPH)
YTD Gains as of March 23: 85%
Switzerland-based medicine software company SOPHiA GENETICS SA (NASDAQ:SOPH) ranks 3rd in our list of the top performing European stocks so far in 2023. Earlier this month, SOPHiA GENETICS SA (NASDAQ:SOPH) posted its Q4 results. Adjusted EPS in the period came in at -$0.17, beating estimates by $0.13. Revenue in the quarter increased by 22.3% on a YoY basis to reach $13.38 million, beating estimates by $0.46 million. For 2023, SOPHiA GENETICS SA (NASDAQ:SOPH) expects its reported revenue growth to come in at 30% or above.
At the end of the fourth quarter of 2022, 5 hedge funds tracked by Insider Monkey reported owning stakes in SOPHiA GENETICS SA (NASDAQ:SOPH).
2. MoonLake Immunotherapeutics (NASDAQ:MLTX)
YTD Gains as of March 23: 92%
MoonLake Immunotherapeutics (NASDAQ:MLTX) is a Swiss biotech company that is working to use Sonelokimab, a novel investigational Nanobody, for the treatment of inflammatory diseases. MoonLake Immunotherapeutics (NASDAQ:MLTX) has gained about 92% year to date through March 23. In February, Cantor Fitzgerald started covering MoonLake Immunotherapeutics (NASDAQ:MLTX) with an Overweight rating. The firm cited a whopping $1.5 billion potential for Sonelokimab.
As of the end of the fourth quarter of 2022, 12 hedge funds tracked by Insider Monkey had stakes in MoonLake Immunotherapeutics (NASDAQ:MLTX).
1. ERYTECH Pharma S.A. (NASDAQ:ERYP)
YTD Gains as of March 23: 133%
France-based ERYTECH Pharma S.A. (NASDAQ:ERYP) makes red blood cell-based therapeutics for cancer and orphan diseases. ERYTECH Pharma S.A. (NASDAQ:ERYP) has gained about 133% in 2023 through March 23. ERYTECH Pharma S.A. (NASDAQ:ERYP) on March 22 posted its full-year 2022 results. Net loss in the period came in at €0.2 million, which was a €53.7 million improvement on a YoY basis.
3 hedge funds in the Insider Monkey database of hedge funds had stakes in ERYTECH Pharma S.A. (NASDAQ:ERYP) as of the end of the fourth quarter of 2022. The biggest stakeholder of ERYTECH Pharma S.A. (NASDAQ:ERYP) was Ian Cumming and Joseph Steinberg’s Leucadia National which had a $189,000 stake in the company.
You can also take a peek at 15 Most Promising Dividend Stocks According to Analysts and 15 Most Promising Long-Term Stocks.
